<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Bevacizumab, a humanized anti-vascular endothelial growth factor monoclonal antibody, has showed clinical benefits in patients with <z:e sem="disease" ids="C0948380" disease_type="Neoplastic Process" abbrv="">metastatic colorectal cancer</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain><z:hpo ids='HP_0000704'>Periodontitis</z:hpo> has been observed infrequently in bevacizumab-containing chemotherapy in clinical practice </plain></SENT>
<SENT sid="2" pm="."><plain>The purpose of this study was to retrospectively investigate bevacizumab-related <z:hpo ids='HP_0000704'>periodontitis</z:hpo> in <z:e sem="disease" ids="C0948380" disease_type="Neoplastic Process" abbrv="">metastatic colorectal cancer</z:e> patients </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: From January 2008 to March 2010, 274 patients received bevacizumab-containing chemotherapy at the National <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">Cancer</z:e> Center Hospital in Tokyo </plain></SENT>
<SENT sid="4" pm="."><plain>Patients who had consulted the dentist for <z:hpo ids='HP_0000704'>periodontitis</z:hpo> were included in the study </plain></SENT>
<SENT sid="5" pm="."><plain>We examined the interval between the initiation of the first bevacizumab administration and the day of the consultation with the dentist </plain></SENT>
<SENT sid="6" pm="."><plain><z:hpo ids='HP_0000704'>Periodontitis</z:hpo> was evaluated before and after conservative therapy </plain></SENT>
<SENT sid="7" pm="."><plain>RESULTS: Twenty-six patients (9.5 % of the 274 metastatic <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> patients) were included in this study </plain></SENT>
<SENT sid="8" pm="."><plain>The median age was 60 years (range 30-79 years) </plain></SENT>
<SENT sid="9" pm="."><plain>Nineteen (73 %) patients had a good performance status of 0 </plain></SENT>
<SENT sid="10" pm="."><plain>The combination regimens used with bevacizumab were infusional <z:chebi fb="0" ids="46345">5-fluorouracil</z:chebi>, leucovorin, and <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi> (FOLFOX, 53 %); infusional <z:chebi fb="0" ids="46345">5-fluorouracil</z:chebi>, leucovorin, and irinotecan (FOLFIRI, 27 %); <z:chebi fb="0" ids="31348">capecitabine</z:chebi> + <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi> (CapeOX, 8 %); S-1 + <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi> (8 %); and S-1 + irinotecan (4 %) </plain></SENT>
<SENT sid="11" pm="."><plain>The median time from bevacizumab administration to the consultation with a dentist for <z:hpo ids='HP_0000704'>periodontitis</z:hpo> was 69 days (range 12-390 days), and the median number of bevacizumab administrations was 3.5 (range 1-25) </plain></SENT>
<SENT sid="12" pm="."><plain>After conservative therapy, 22 (85 %) patients with <z:hpo ids='HP_0000704'>periodontitis</z:hpo> showed an improvement </plain></SENT>
<SENT sid="13" pm="."><plain>CONCLUSIONS: <z:hpo ids='HP_0000704'>Periodontitis</z:hpo> occurred frequently in patients receiving bevacizumab </plain></SENT>
<SENT sid="14" pm="."><plain>The conservative therapy for <z:hpo ids='HP_0000704'>periodontitis</z:hpo> was very effective, and the prophylaxitic treatment was important </plain></SENT>
</text></document>